LIGAND PHARMACEUTICALS INC (LGND) Stock
2 members of Congress disclosed 5 trades in LGND since 2020: 5 purchases and 0 sales, most recently Gilbert Cisneros (purchase, May 29, 2026). 2 of the hedge funds AlphaScala tracks reported LGND in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $17.86M. Company insiders reported 0 open-market buys and 24 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which members of Congress traded LIGAND PHARMACEUTICALS INC (LGND)?
Most recent: Gilbert Cisneros (purchase, May 29, 2026); records start Apr 3, 2020.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2026-05-29 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-03-03 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-01-15 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-01-05 | purchase | $1k – $15k |
| Katherine Clark D-MA · House | 2020-04-03 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 20, 2026.
See all LGND political trades →Which hedge funds own LGND?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 57K | $17.86M | -28% |
| Millennium Management Israel Englander | 4K | $1.26M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are LIGAND PHARMACEUTICALS INC insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 2, 26 | Reardon Andrew | CLO & Secretary | SELL | 833 | $252K |
| Oct 2, 26 | Reardon Andrew | CLO & Secretary | SELL | 2.0K | $600K |
| Oct 2, 26 | Reardon Andrew | CLO & Secretary | SELL | 1.5K | $467K |
| Oct 2, 26 | Reardon Andrew | CLO & Secretary | SELL | 404 | $124K |
| Oct 2, 26 | Reardon Andrew | CLO & Secretary | SELL | 235 | $72K |
| Oct 2, 26 | Reardon Andrew | CLO & Secretary | SELL | 17 | $5K |
| Sep 10, 26 | Zimmermann Martine | Director | SELL | 1.2K | $342K |
| Sep 3, 26 | Reardon Andrew | CLO & Secretary | SELL | 300 | $85K |
| Sep 3, 26 | Reardon Andrew | CLO & Secretary | SELL | 1.8K | $513K |
| Sep 3, 26 | Reardon Andrew | CLO & Secretary | SELL | 2.1K | $606K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →LGND price chart
Powered by TradingViewWhat does LIGAND PHARMACEUTICALS INC do?
Ligand Pharmaceuticals Inc. is a biopharmaceutical company that develops, acquires, and out-licenses proprietary technologies to assist pharmaceutical and biotechnology firms in discovering and developing novel medicines. It operates through research services and royalty-generating businesses, focusing on a diversified portfolio of platforms that support therapeutic candidates across various disease areas. Key offerings include Captisol®, a chemically modified cyclodextrin that enhances the solubility, stability, and delivery of small-molecule drugs, and OmniAb™, an antibody discovery and optimization platform. Additional services encompass absorption, distribution, metabolism, and excretion (ADME) testing via subsidiaries Cyprotex and Absorption Systems, aiding early- and late-stage drug development. The company generates revenue from royalties on commercialized products, license and milestone payments, and sales of its Captisol material, partnering with leading global biopharmaceutical entities. Founded in 1987 and headquartered in San Diego, California, Ligand Pharmaceuticals Inc. plays a vital role in advancing drug innovation through technology licensing and collaborative research.